Integral Derivatives’s GSK GSK Stock Holding History

Integral Derivatives’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,480	Closed	-$287K	–	804
2017 Q4	$287K	Sell	6,480 -160	-2%	-$7.39K	0.01%	886
2017 Q3	$337K	Sell	6,640 -80	-1%	-$4.06K	0.01%	860
2017 Q2	$362K	Buy	6,720 +1,200	+22%	+$64K	0.01%	804
2017 Q1	$291K	Sell	5,520 -11,280	-67%	-$572K	0.01%	915
2016 Q4	$809K	Buy	16,800 +6,320	+60%	+$312K	0.02%	567
2016 Q3	$565K	Buy	10,480 +4,320	+70%	+$237K	0.01%	593
2016 Q2	$334K	Buy	6,160 +2,160	+54%	+$114K	0.01%	709
2016 Q1	$203K	Hold	4,000	–	–	0.01%	745
2015 Q4	$202K	Buy	+4,000	New	+$204K	0.01%	925
2015 Q1	–	Sell	-8,000	Closed	-$427K	–	1206
2014 Q4	$427K	Sell	8,000 -11,840	-60%	-$662K	0.01%	966
2014 Q3	$1.14M	Buy	+19,840	New	+$1.22M	0.02%	652

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Integral Derivatives's GSK Position: Q2 2017 in Review

Integral Derivatives sold out of GSK (GSK) in Q2 2017, closing a stake of 6,539 shares — an estimated $349K sold.

Integral Derivatives first reported a position in GSK in Q4 2013 and held it in 7 quarters. The position peaked at $1.68M in Q4 2013. 779 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

Integral Derivatives reported no remaining GSK position as of Q2 2017 after selling out during the quarter.
Integral Derivatives sold 6,539 GSK shares in Q2 2017, an estimated $349K.
Integral Derivatives first reported a position in GSK in Q4 2013 and held it in 7 quarters.
Integral Derivatives's GSK position peaked at $1.68M in Q4 2013.
779 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Integral Derivatives's 13F filing for Q2 2017, filed 14 Aug 2017.